Evidence map›Paper›PMID 26087310›Full record

ArticleOncotarget2015

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells.

Arianna De Luca, Marco Fiorillo, Maria Peiris-Pagès, Bela Ozsvari, Duncan L Smith, Rosa Sanchez-Alvarez, Ubaldo E Martinez-Outschoorn, Anna Rita Cappello, Vincenzo Pezzi, Michael P Lisanti and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 2 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 2 syntheses or guidelines pooled it, 251 citations in OpenAlex.

  1. Pooled it
  2. PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Arianna De LucaThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
Marco FiorilloThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
Maria Peiris-PagèsThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
Bela OzsvariThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
Duncan L SmithThe Cancer Research UK Manchester Institute, University of Manchester, UK.
Rosa Sanchez-AlvarezThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
Ubaldo E Martinez-OutschoornThe Sidney Kimmel Cancer Center, Philadelphia, PA, USA.
Anna Rita CappelloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy.
Vincenzo PezziDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy.
Michael P LisantiThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
Federica SotgiaThe Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK.
University of Manchester · GBUniversity of Calabria · ITCancer Research UK Manchester Institute · GBSidney Kimmel Cancer Center · US

Funding

Cancer Research UK
6 · The paper itself

Abstract

Here, we show that new mitochondrial biogenesis is required for the anchorage independent survival and propagation of cancer stem-like cells (CSCs). More specifically, we used the drug XCT790 as an investigational tool, as it functions as a specific inhibitor of the ERRα-PGC1 signaling pathway, which governs mitochondrial biogenesis. Interestingly, our results directly demonstrate that XCT790 efficiently blocks both the survival and propagation of tumor initiating stem-like cells (TICs), using the MCF7 cell line as a model system. Mechanistically, we show that XCT790 suppresses the activity of several independent signaling pathways that are normally required for the survival of CSCs, such as Sonic hedgehog, TGFβ-SMAD, STAT3, and Wnt signaling. We also show that XCT790 markedly reduces oxidative mitochondrial metabolism (OXPHOS) and that XCT790-mediated inhibition of CSC propagation can be prevented or reversed by Acetyl-L-Carnitine (ALCAR), a mitochondrial fuel. Consistent with our findings, over-expression of ERRα significantly enhances the efficiency of mammosphere formation, which can be blocked by treatment with mitochondrial inhibitors. Similarly, mammosphere formation augmented by FOXM1, a downstream target of Wnt/β-catenin signaling, can also be blocked by treatment with three different classes of mitochondrial inhibitors (XCT790, oligomycin A, or doxycycline). In this context, our unbiased proteomics analysis reveals that FOXM1 drives the expression of >90 protein targets associated with mitochondrial biogenesis, glycolysis, the EMT and protein synthesis in MCF7 cells, processes which are characteristic of an anabolic CSC phenotype. Finally, doxycycline is an FDA-approved antibiotic, which is very well-tolerated in patients. As such, doxycycline could be re-purposed clinically as a 'safe' mitochondrial inhibitor, to target FOXM1 and mitochondrial biogenesis in CSCs, to prevent tumor recurrence and distant metastasis, thereby avoiding patient relapse.

Indexed as

Organelle BiogenesisAcetylcarnitineBreast NeoplasmsCell AdhesionCell ProliferationCell SurvivalChromatography, LiquidDoxycyclineERRalpha Estrogen-Related ReceptorForkhead Box Protein M1Forkhead Transcription FactorsGlycolysisHumansMCF-7 CellsMitochondriaNeoplastic Stem CellsAcetylcarnitineDoxycyclineERRalpha Estrogen-Related ReceptorForkhead Box Protein M1Forkhead Transcription FactorsFOXM1 protein, humanNitrilesOligomycinsReceptors, EstrogenThiazolesXCT790doxycyclinedrug repurposingERR-αPGC1-α/βXCT790

Identifiers

PMID26087310
PMCPMC4558115
OpenAlexW1897724420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.